These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. β-adrenergic sweat test in children with inconclusive cystic fibrosis diagnosis: Do we need new reference ranges? Zampoli M; Verstraete J; Nguyen-Khoa T; Sermet-Gaudelus I; Zar HJ; Gonska T; Morrow BM Pediatr Pulmonol; 2023 Jan; 58(1):187-196. PubMed ID: 36193559 [TBL] [Abstract][Full Text] [Related]
4. β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Quinton P; Molyneux L; Ip W; Dupuis A; Avolio J; Tullis E; Conrad D; Shamsuddin AK; Durie P; Gonska T Am J Respir Crit Care Med; 2012 Oct; 186(8):732-9. PubMed ID: 22859523 [TBL] [Abstract][Full Text] [Related]
5. Iontophoretic beta-adrenergic stimulation of human sweat glands: possible assay for cystic fibrosis transmembrane conductance regulator activity in vivo. Shamsuddin AK; Reddy MM; Quinton PM Exp Physiol; 2008 Aug; 93(8):969-81. PubMed ID: 18441335 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome. Gunnett MA; Baker E; Mims C; Self ST; Gutierrez HH; Guimbellot JS Front Pediatr; 2023; 11():1127659. PubMed ID: 36969284 [TBL] [Abstract][Full Text] [Related]
7. A simplified cyclic adenosine monophosphate-mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function. Callen A; Diener-West M; Zeitlin PL; Rubenstein RC J Pediatr; 2000 Dec; 137(6):849-55. PubMed ID: 11113843 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/CF screen-positive, inconclusive diagnosis. Terlizzi V; Claut L; Colombo C; Tosco A; Castaldo A; Fabrizzi B; Lucarelli M; Cimino G; Carducci C; Dolce D; Biffi A; Bonomi P; Timpano S; Padoan R Pediatr Pulmonol; 2021 Dec; 56(12):3785-3791. PubMed ID: 34549893 [TBL] [Abstract][Full Text] [Related]
9. Sweat gland bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and assessment of CFTR function in cystic fibrosis. Gonska T; Ip W; Turner D; Han WS; Rose J; Durie P; Quinton P Thorax; 2009 Nov; 64(11):932-8. PubMed ID: 19734129 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Ren CL; Desai H; Platt M; Dixon M Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969 [TBL] [Abstract][Full Text] [Related]
11. Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening. Munck A; Bourmaud A; Bellon G; Picq P; Farrell PM; Pediatr Pulmonol; 2020 Apr; 55(4):918-928. PubMed ID: 31916691 [TBL] [Abstract][Full Text] [Related]
13. How the sweat gland reveals levels of CFTR activity. Wine JJ J Cyst Fibros; 2022 May; 21(3):396-406. PubMed ID: 35184981 [TBL] [Abstract][Full Text] [Related]
14. CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the β-adrenergic sweat rate assay. Pallenberg ST; Junge S; Ringshausen FC; Sauer-Heilborn A; Hansen G; Dittrich AM; Tümmler B; Nietert M J Cyst Fibros; 2022 May; 21(3):442-447. PubMed ID: 34756683 [TBL] [Abstract][Full Text] [Related]
15. A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. Terlizzi V; Claut L; Tosco A; Colombo C; Raia V; Fabrizzi B; Lucarelli M; Angeloni A; Cimino G; Castaldo A; Marsiglio L; Timpano S; Cirilli N; Moroni L; Festini F; Piccinini P; Zavataro L; Bonomi P; Taccetti G; Southern KW; Padoan R J Cyst Fibros; 2021 Sep; 20(5):828-834. PubMed ID: 33883100 [TBL] [Abstract][Full Text] [Related]
16. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. ; Borowitz D; Parad RB; Sharp JK; Sabadosa KA; Robinson KA; Rock MJ; Farrell PM; Sontag MK; Rosenfeld M; Davis SD; Marshall BC; Accurso FJ J Pediatr; 2009 Dec; 155(6 Suppl):S106-16. PubMed ID: 19914443 [TBL] [Abstract][Full Text] [Related]
17. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis. Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630 [TBL] [Abstract][Full Text] [Related]
20. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Sermet-Gaudelus I; Girodon E; Roussel D; Deneuville E; Bui S; Huet F; Guillot M; Aboutaam R; Renouil M; Munck A; des Georges M; Iron A; Thauvin-Robinet C; Fajac I; Lenoir G; Roussey M; Edelman A Thorax; 2010 Jun; 65(6):539-44. PubMed ID: 20522854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]